Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:4
  • preuzimanja u poslednjih 30 dana:3
članak: 2 od 32  
Back povratak na rezultate
Vojnosanitetski pregled
2019, vol. 76, br. 10, str. 1071-1076
jezik rada: engleski
vrsta rada: prikaz slučaja
doi:10.2298/VSP170910180J
Creative Commons License 4.0
Kuda dalje sa terapijskim monitoringom antiepileptika?
Univerzitet u Kragujevcu, Medicinski fakultet

e-adresa: slobodan.jankovic@medf.kg.ac.rs

Sažetak

(ne postoji na srpskom)
<Conclusion>Despite a relatively long history of TDM use within the framework of epilepsy treatment, we are using only small part of possibilities it offers, in the first place because of lack of specific knowledge. In order to use full capacity of TDM in the future for maximum benefit of patients with epilepsy, we need to establish the seizure type and severity-specific therapeutic ranges for those anticonvulsants where TDM has clinical significance, as well as to prove the positive effects of TDM on a wide spectrum of treatment outcomes. The development of non-invasive TDM methods, the point-of-care tests and reliable methods for routine measurement of free drug concentrations in plasma are also the areas where progress could empower TDM of anticonvulsants and bring new qualities. However, we should acknowledge that for many years, the TDM has been successfully used for adjusting doses of the first-generation anticonvulsants, provided that important confounding factors were taken into account, like hypoalbuminemia, hypervolemia, acid-base disequilibrium, and others.

Ključne reči

antikonvulzivi; epilepsija; lekovi, monitoring; doziranje, oblici; plazma; pljuvačka

Reference

André, P., Novy, J., Decosterd, L.A., Buclin, T., Rothuizen, L.E. (2015) Therapeutic drug monitoring of antiepileptic drugs in the 21st century. Epileptologie, 32, 78-84
Babaei, A., Eslamai, M.H. (2007) Evaluation of therapeutic drug level monitoring of phenobarbital, phenytoin and carbamazepine in Iranian epileptic patients. Int. Journal of Clinical Pharmacology and Therapeutics, 45(02), 121-125
Baldelli, S., Cattaneo, D., Giodini, L., Baietto, L., di Perri, G., D'avolio, A., Clementi, E.D. (2015) Development and validation of a HPLC-UV method for the quantification of antiepileptic drugs in dried plasma spots. Clinical Chemistry and Laboratory Medicine (CCLM), 53(3), 435-444
Battino, D., Croci, D., Granata, T., Estienne, M., Pisani, F., Avanzini, G. (1997) Lamotrigine plasma concentrations in children and adults: Influence of age and associated therapy. Ther Drug Monit, 19(6), 620-627
Beghi, E., Trevisan, D., Tognoni, G. (1992) Use of plasma levels for antiepileptic drug monitoring in clinical practice: Gruppo Collaborativo per lo Studio dell'Epilessia. Ital J Neurol Sci, 13(1), 59-65
Benetello, P., Furlanut, M., Baraldo, M., Tonon, A., Furlanut, M. (2002) Therapeutic drug monitoring of lamotrigine in patients suffering from resistant partial seizures. European Neurology, 48(4), 200-203
Bentué-Ferrer, D., Tribut, O., Verdier, M.C. (2010) Le groupe suivi thérapeutique pharmacologique de la société française de pharmacologie et de thérapeutique. Therapie, 65(1), 51-55
Bentué-Ferrer, D., Tribut, O., Verdier, M.C. (2010) Le groupe suivi théra-peutique pharmacologique de la société française de pharmacologie et de thérapeutique: Therapeutic drug monitoring of pregabaline. Therapie, 65(1), 47-49
Bentué-Ferrer, D., Tribut, O., Verdier, M.C. (2010) Le groupe suivi thérapeutique pharmacologique de la Société Française de pharmacologie et de thérapeutique: Therapeutic drug monitoring of vigabatrin. Therapie, 65(1), 23-27
Bentué-Ferrer, D., Tribut, O., Verdier, M.C. (2010) Le groupe suivi théra-peutique pharmacologique de la société française de pharmacologie et de thérapeutique: Therapeutic drug monitoring of lamotrigine. Therapie, 65(1), 39-46
Briscoe, S.E., McWhinney, B.C., Lipman, J., Roberts, J.A., Ungerer, J.P.J. (2012) A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. Journal of Chromatography B, 907, 178-184
Charfi, R., Lakhal, M., Klouz, A., Trabelsi, S., Salouage, I. (2015) Therapeutic drug monitoring of valproic acid in children: A prospective study of the effect of the compliance and the economic level on the trough plasmatic concentrations and epileptic seizures. Therapie, 70(5), 415-424
Dupont, S., Biraben, A., Lavernhe, G., Marquet, T., Allaf, B. (2013) Management and monitoring of patients treated with zonisamide: The OZONE study. Epileptic Disorders, 15(3), 278-288
Dwivedi, R., Singh, M., Kaleekal, T., Gupta, Y.K., Tripathi, M. (2016) Concentration of antiepileptic drugs in persons with epilepsy: A comparative study in serum and saliva. International Journal of Neuroscience, 126(11), 972-978
Dwivedi, R., Gupta, Y.K., Singh, M., Joshi, R., Tiwari, P., Kaleekal, T., Tripathi, M. (2015) Correlation of saliva and serum free valproic acid concentrations in persons with epilepsy. Seizure, 25, 187-190
Eadie, M.J. (1997) Indications for plasma drug monitoring in patients with epilepsy: Implications for reducing costs. Pharmacoeconomics, 11(4), 343-349
Ferrari, A.R., Guerrini, R., Gatti, G., Alessandri, M.G., Bonanni, P., Perucca, E. (2003) Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. Therapeutic Drug Monitoring, 25(6), 700-708
Franco, V., Marchiselli, R., Fattore, C., Tartara, E., de Sarro, G., Russo, E., Perucca, E. (2016) Development and validation of an HPLC-UV assay for the therapeutic monitoring of the new antiepileptic drug perampanel in human plasma. Therapeutic Drug Monitoring, 38(6), 744-750
Franco, V., French, J.A., Perucca, E. (2016) Challenges in the clinical development of new antiepileptic drugs. Pharmacological Research, 103, 95-104
French, J.A., Gazzola, D.M. (2011) New generation antiepileptic drugs: What do they offer in terms of improved tolerability and safety?. Therapeutic Advances in Drug Safety, 2(4), 141-158
Fröscher, W., Schier, K.R., Hoffmann, M., Meyer, A., May, T.W., Rambeck, B. (2005) Topiramate: A prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy. Epileptic Disord, 7(3), 237-248
Fröscher, W., Keller, F., Vogt, H., Krämer, G. (2002) Prospective study on concentration-efficacy and concentration-toxicity: Correlations with lamotrigine serum levels. Epileptic Disord, 4(1), 49-56
Glauser, T.A., Pippenger, C.E. (2000) Controversies in blood-level monitoring: Reexamining its role in the treatment of epilepsy. Epilepsia, 41(s8), S6-S15
Goldenberg, M.M. (2010) Overview of drugs used for epilepsy and seizures: Etiology, diagnosis, and treatment. Pharm Ther, 35(7), 392-415
Greenberg, R.G., Melloni, C., Wu, H., Gonzalez, D., Ku, L., Hill, K.D. (2016) Therapeutic index estimation of antiepileptic drugs: A systematic literature review approach. Clin Neuropharmacol, 39(5), 232-240
Jacob, S., Nair, A.B. (2016) An updated overview on therapeutic drug monitoring of recent antiepileptic drugs. Drugs in R&D, 16(4), 303-316
Jannuzzi, G., Cian, P., Fattore, C., Gatti, G., Bartoli, A., Monaco, F., Perucca, E. (2000) A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. Epilepsia, 41(2), 222-230
Jansen, A.J., Hunfeld, N.G., Bommel, J., Koch, B.C., Gelder, T. (2012) Therapeutic drug monitoring of free fraction valproic acid in patients with hypoalbuminaemia. Neth J Med, 70(7), 329-329
Johannessen, L.C., Beiske, G., Baftiu, A., Burns, M.L., Johannessen, S.I. (2015) Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. Seizure, 28, 88-91
Johannessen, S.I., Battino, D., Berry, D.J., Bialer, M., Krämer, G., Tomson, T., Patsalos, P.N. (2003) Therapeutic drug monitoring of the newer antiepileptic drugs. Therapeutic Drug Monitoring, 25(3), 347-363
Klein, P., Tyrlikova, I., Brazdil, M., Rektor, I. (2016) Brivaracetam for the treatment of epilepsy. Expert Opinion on Pharmacotherapy, 17(2), 283-295
Krasowski, M.D., Penrod, L.E. (2012) Clinical decision support of therapeutic drug monitoring of phenytoin: Measured versus adjusted phenytoin plasma concentrations. BMC Medical Informatics and Decision Making, 12(1), 7-7
Luszczki, J.J. (2009) Third-generation antiepileptic drugs: Mechanisms of action, pharmacokinetics and interactions. Pharmacological Reports, 61(2), 197-216
May, T.W., Boor, R., Rambeck, B., Jürgens, U., Korn-Merker, E., Brandt, C. (2011) Serum concentrations of rufinamide in children and adults with epilepsy: The influence of dose, age, and comedication. Therapeutic Drug Monitoring, 33(2), 214-221
Melten, J.W., Wittebrood, A.J., Willems, H.J.J., Faber, G.H., Wemer, J., Faber, D.B. (1985) Comparison of equilibrium dialysis, ultrafiltration, and gel permeation chromatography for the determination of free fractions of phenobarbital and phenytoin. Journal of Pharmaceutical Sciences, 74(6), 692-694
Meneghello, A., Tartaggia, S., Alvau, M.D., Polo, F., Toffoli, G. (2017) Biosensing technologies for therapeutic drug monitoring. Curr Med Chem, Jul 20
Miles, M.V., Tennison, M.B., Greenwood, R.S. (1991) Intraindividual variability of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. Therapeutic Drug Monitoring, 13(2), 166-171
Milovanović, B., Tomović, D., Janković, S.M., Grubor, I., Nikolić, L., Nikolić, M., Mijajlović, M., Mrvić, S., Divjak, A., Milojević, A., Đoković, J., Prokić, A., Bukonjić, A., Sekulić, M., Matić, V. (2017) Faktori koji utiču na strah od igle kod studenata medicine i farmacije. Acta Facultatis Medicae Naissensis, vol. 34, br. 2, str. 147-158
Mula, M. (2016) Third generation antiepileptic drug monotherapies in adults with epilepsy. Expert Review of Neurotherapeutics, 16(9), 1087-1092
Patsalos, P.N., Berry, D.J. (2013) Therapeutic drug monitoring of antiepileptic drugs by use of saliva. Therapeutic Drug Monitoring, 35(1), 4-29
Patsalos, P.N., Berry, D.J., Bourgeois, B.F.D., Cloyd, J.C., Glauser, T.A., Johannessen, S.I., Leppik, I.E., Tomson, T., Perucca, E. (2008) Antiepileptic drugsbest practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia, 49(7), 1239-1276
Pennell, P.B., Peng, L., Newport, D.J., Ritchie, J.C., Koganti, A., Holley, D.K., Newman, M., Stowe, Z.N. (2008) Lamotrigine in pregnancy: Clearance, therapeutic drug monitoring, and seizure frequency. Neurology, 70(Issue 22, Part 2), 2130-2136
Perucca, E. (1984) Free level monitoring of antiepileptic drugs clinical usefulness and case studies. Clinical Pharmacokinetics, 9(Supplement 1), 71-78
Pippenger, C.E. (2006) Therapeutic drug monitoring assay development to improve efficacy and safety. Epilepsy Research, 68(1), 60-63
Sanavio, B., Krol, S. (2015) On the slow diffusion of point-of-care systems in therapeutic drug monitoring. Frontiers in Bioengineering and Biotechnology, 3, 20-20
Schmidt, D., Haenel, F. (1984) Therapeutic plasma levels of phenytoin, phenobarbital, and carbamazepine: Individual variation in relation to seizure frequency and type. Neurology, 34(9), 1252-1255
Sharma, S., Joshi, S., Mukherji, S., Bala, K., Tripathi, C.B. (2009) Therapeutic drug monitoring: appropriateness and clinical utility in neuropsychiatry practice. American Journal of Therapeutics, 16(1), 11-16
Stepanova, D., Beran, R.G. (2014) Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs). Seizure, 23(5), 371-376
Svendsen, T., Brodtkorb, E., Reimers, A., Molden, E., Sætre, E., Johannessen, S.I., Johannessen, L.C. (2017) Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate: A national approach to the evaluation of therapeutic drug monitoring data and clinical outcome. Epilepsy Research, 129, 125-131
Svendsen, T., Brodtkorb, E., Baftiu, A., Burns, M.L., Johannessen, S.I., Johannessen, L.C. (2017) Therapeutic drug monitoring of lacosamide in Norway: Focus on pharmacokinetic variability, efficacy and tolerability. Neurochemical Research, 42(7), 2077-2083
Tribut, O., Bentué-Ferrer, D., Verdier, M.C. (2010) Le groupe suivi théra-peutique pharmacologique de la Société Française de Pharmacologie et de Thérapeutique: Therapeutic drug monitoring of felbamate. Therapie, 65(1), 35-38
Walson, P.D. (1985) Practical problems of therapeutic drug monitoring of anticonvulsants. Brain and Development, 7(2), 116-121